Uncertainty on a number of fronts, in particular regarding certain technical aspects of complying with the new criteria has to some extent compounded the difficulties in meeting the complex and onerous certification and reporting requirements required to gain the STS seal of approval. The more beneficial capital treatment for banks, funds and other investors such as insurance companies, some of whom are currently priced out of the securitisation sector in Europe, should improve pricing levels and funding costs. However, meeting the complex criteria required for STS qualification is burdensome.


CONTACTS

bioImage

Sam Ellis

Senior Vice President

+44 20 7466 1645

bioImage

Jennifer Jones

Vice President

+44 20 7466 1647

bioImage

Charles Leahy

Vice President

+44 20 7466 1637

bioImage

Tom Davies

Regional Head of Fiduciary - Europe

+352 26 68 62 33

bioImage

Stephen O'Donnell

Regional Head of Fiduciary - Europe

+353 1 697 3244

bioImage

Jan Hendrik Siemssen

Senior Vice President

+31 20 570 6820

*
*
*
*

Please note that your email may be received and read by other Maples and Calder lawyers in addition to your intended recipient.

*
*
*

Please note that your email may be received and read by other Maples Group employees in addition to your intended recipient.

Connect

Want to get in touch ?

Contact Us